Clinical trial
Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study
NCT00225017 · Northwestern University, Other · Completed
Key facts
| NCT number | NCT00225017 |
|---|---|
| Title | Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study |
| Official title | Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study: Endothelial Function in HIV-Infected Subjects Switched to an Atazanavir Regimen |
| Acronym | SABAR |
| Lead sponsor | Northwestern University, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infection, Hyperlipidemia |
| Intervention type | Drug |
| Interventions | Atazanavir, current antiretroviral regimen |
| Enrollment | 50 |
| Start date | Jun 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Sep 23, 2005 |
| Last update posted | Aug 2, 2012 |
| Countries | Argentina, Italy, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: